Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retinal Deep PhenotypingTM Platform for Cerebral Amyloid Status Evaluation: a Validation Study

NCT05107882 is registered in ClinicalTrials.gov with Optina Diagnostics Inc. as lead sponsor.

NCT NCT05107882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05107882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retinal Deep PhenotypingTM Platform for Cerebral Amyloid Status Evaluation: a Validation Study
Lead sponsor
Optina Diagnostics Inc.
Phase
Observational
Overall status
Completed
Start date
June 7, 2022
Completion date
July 25, 2024
Enrollment
466 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment, mild dementia